CC BY
14
Abstracts. PHYTOPHARM 2017
HT22 cells from the cytotoxic effects of glutamate or NMDA and the possible anti-inflammatory properties on LPS-activated macrophages (MO).
Differentiated HT22 cells were pre-treated with STW 3-VI to investigate the protective effects against glutamate or NMDA cytotoxicity. The anti-inflammatory properties of STW 3-VI were evaluated by quantification of the TNF release on LPS activated PMA-differentiated THP 1 MO using ELISA assay and the mRNA expression of TNF and IL-6 by qRT-PCR. Glutamate or NMDA (0.1mM) induced 30% cytotoxicity in HT22 cells.
Pre-incubation (24h) of STW 3-VI improved the viability by 30%, compared to the control. Pre-treatment (48h) of LPS-activated MO with STW 3-VI induced a significant lowering (54%, 64% and 53%) of TNF
release. QRT-PCR revealed that 48 h pre-treatment with STW 3-VI inhibits the mRNA expression of IL-6 and TNF respectively by LPS-activated MO.
STW 3-VI protects hippocampal cells from glutamate or NMDA induced cytotoxicity and activates the antiinflammatory defense by inhibition of the cytokine production by MO, These effects might be relevant for the therapeutic effects of STW 3-VI in psychic depression.
References:
1. Breyer A et al. 2007. Phytomedicine. 14:250-255.
2. Denke A et al. 2000. Drug Res. 50 (5):415-419.
3. Gastpar M, Singer A, Zeller K. 2006. Pharmacopsy-chiatry. 39:66-75.
INFLAMMATION AS A TARGET: DIFFERENT MODE OF ACTION OF HERBAL MEDICINES AND NSAIDS
© Kelber Olaf1, Samstag Fabienne1, Nieber Karen2
11nnovation and Development, Phytomedicines Supply and Development Center, Bayer Consumer Health Division, Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany; 2 Pharmaceutical Institute, Leipzig University, Leipzig, Germany
Recent studies have shown that systemic responses of increased circulating lymphocytes and elevated proinflammatory cytokines and subtle inflammation are a reason also of many functional diseases, as e.g. functional dyspepsia (FD) and irritable bowel syndrome (IBS). The complexity of these diseases indicates that there are different pathophysiological mechanisms involved.
On the example of the herbal medicinal product STW 5, mechanisms of action involved anti-inflammatory effects were compared to those of NSAIDs.
Data from in vitro studies [1, 2] were revealed and analysed for elucidating possible mechanisms of action underlying the anti-inflammatory effects of STW 5.
STW 5 activated COX-1, but had no effect on COX-2 mRNA expression in contrast to the control substances, like ASS and diclofenac, which inhibited COX-1 and COX-2 mRNA expression. STW 5 inhibited the increased
gene expression and reduced significantly the release of TNF-alpha by activation of adenosine A2A receptors in LPS (100 ng/ml)-stimulated human monocytes, while having no effect in untreated cells. Radiolig and binding assays confirmed the affinity of STW 5 to adenosine A2A receptors.
The mechanism of action of STW 5 as an anti-inflammatory medication without involving COX-1 or COX-2 inhibitory properties is fundamentally different from that of NSAIDs, which may be an important reason for the usefulness of this medicinal product especially in patients with FD and IBS, as indicated by clinical trials and therapeutic use.
References:
1. Michael S et al. 2012. Inflammatory Bowel Disease 3: 41.
2. Bonaterra G A et al. 2008. Z. Phytotherapie 29: S22 therapeutic use.
PRODUCTION AND STANDARDIZATION OF EXTRACTS FROM BIDENS TRIPARTITA, SOLIDAGO CANADENSIS AND AGRIMONIA EUPATORIA
© Kaukhova I.E., Novikova E.K., Chachin D.A.
St. Petersburg State Chemical Pharmaceutical Academy, St-Petersburg, Russia
In the present study, a quantitation of main active substances and antioxidant activity of the dry extracts from Bidens tripartita, Solidago canadensis and Agrimonia eupatoria in the production of medicinal substances was carried out.
The samples of B. tripartite, S. canadensis and A. eupatoria were purchased from a local pharmacy. The dried samples of B. tripartite, S. canadensis and A. eupatoria were extracted by water-alcohol in the ratio 1:20 of different concentrations 40%, 50% and 70%, respectively, in a
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy] vol. 15/2017/suppLement 1
1 31
